About: Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Latest price: $12.93 (-1.97%)
TRVI NASDAQ Trevi Therapeutics Inc
Trevi Therapeutics Inc share price
TRVI price activity
Last Price
$12.930
Change (24hr)
-0.26 USD (-1.97%)
Volume
1.52M
Volume (4w avg)
-
Open
$13.10
Day Range
$12.93 - $13.10
Previous Close
$13.19
Last Trade
12 Oct, 8:00 pm GMT+0
Delayed
12 Oct, 8:00 pm GMT+0
TRVI price performance
Delayed
12 Oct, 8:00 pm GMT+0
TRVI Market Signals